Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

108.97 -2.51 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
64 65 Next >
Price Over Earnings Overview: BioNTech
Via Benzinga
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
From BioNTech SE
Via GlobeNewswire
Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets
With the artificial intelligence boom gaining momentum, we’re likely to see far more interest in AI stocks. 
Via InvestorPlace
Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics
As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other... 
Via Benzinga
Where BioNTech Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for BioNTech
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support
Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v 
Via Benzinga
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger 
Via Benzinga
German Woman Sues BioNTech for €150K Claiming Adverse Effects from COVID-19 Vaccine: What You Need to Know
BioNTech SE (NASDAQ: BNTX) is reportedly scheduled to appear in court on Monday to defend itself against a lawsuit filed by a German woman seeking damages for alleged side effects of BioNTech's... 
Via Benzinga
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO
HighTide Therapeutics filed for an IPO on the Hong Kong Exchange. Additionally, Shanghai Fosun Pharma will partner with the International Finance Corp to build a pharmaceutical production facility and... 
Via Talk Markets
ASCO 2023 – Claudin 6 Makes A Splash In Ovarian Cancer
This year’s 2023 American Society of Clinical Oncology Annual Meeting (ASCO 2023) provided a surprising amount of clinical data relevant to biopharma investors. 
Via Benzinga
ChatGPT's Parent Has No IPO Plans, CNN CEO Chris Licht Out, Kim Kardashian's Bid To Dismiss EthereumMax Lawsuit Rejected: Today's Top Stories
Benzinga Cable Giant CNN Chairman, CEO Chris Licht Moves Out 
Via Benzinga
Another Patent Dispute Emerges: Small Biotech Firm Sues Moderna, Pfizer, and BioNTech Over COVID-19 Vaccine Tech
Pfizer Inc (NYSE: PFE), BioNTech SE (NASDAQ: BNTX), and Moderna Inc (NASDAQ: MRNA) were named in lawsuits by 
Via Benzinga
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Benzinga 
Via Benzinga
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Novavax Inc's (NASDAQ: NVAX) R&D chief Filip Dubovsky expressed confidence that the company's updated COVID-19 vaccine, already in production, will offer protection against the rapidly emerging... 
Via Benzinga
3 Ugly Stocks That Actually Hide Beautiful Potential
While these underrated stocks with potential has about as much appeal as brown guacamole, they’re actually quite intriguing. 
Via InvestorPlace
Why Shares of BioNTech Rose Friday
The company released positive trial data for a non-small cell lung cancer therapy. 
Via The Motley Fool
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
BioNTech is testing out a next-generation form of Yervoy, hoping to reduce side effects. 
Via Investor's Business Daily
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
From BioNTech SE
Via GlobeNewswire
7 Deeply Undervalued Growth Stocks to Buy in June
Investors may see significant rewards betting on these best undervalued growth stocks for June. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amazon's Prime Video Trolls Netflix's Password Crackdown, Tesla Data Leak Exposes Safety Nightmare, Elon Musk's Brain Chip Company Gets FDA Nod For Human Trial: Top Stories For Today
Benzinga 
Via Benzinga
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
Via Benzinga
Why Pfizer Stock Slipped by 2% Today
The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares. 
Via The Motley Fool
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
In an annual general meeting, BioNTech SE's (NASDAQ: BNTX) CEO and co-founder Ugur Sahin told shareholders the company is working on COVID-19 vaccines targeting XBB.1.5 strains in line with... 
Via Benzinga
As Debt Ceiling Talks Wobble, Investors Look To May Fed Minutes, Nvidia Earnings For Direction
(Wednesday market open) Investors seeking distraction from the ticking debt ceiling countdown clock get some this afternoon in the form of Federal Reserve meeting minutes and Nvidia (NASDAQ: NVDA)... 
Via Benzinga
Why Novavax, Pfizer And BioNTech Shares Are Rising Today
Shares of vaccine makers Novavax Inc (NASDAQ: NVAX), Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) a 
Via Benzinga
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years
Both are experiencing a bit of a hangover from declining COVID-19-related sales. 
Via The Motley Fool
WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake
An advisory group for the World Health Organization said the current crop of shots should be updated to target the currently dominant XBB strains for the 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.